Head to Head Contrast: Oculis (NASDAQ:OCS) and Xeris Biopharma (NASDAQ:XERS)

Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Oculis (NASDAQ:OCS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Xeris Biopharma and Oculis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xeris Biopharma -1.76% 147.75% 6.03%
Oculis -8,613.92% -39.24% -33.45%

Analyst Recommendations

This is a summary of recent ratings and target prices for Xeris Biopharma and Oculis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma 1 1 4 0 2.50
Oculis 1 0 7 0 2.75

Xeris Biopharma presently has a consensus price target of $17.00, indicating a potential upside of 2.29%. Oculis has a consensus price target of $38.57, indicating a potential upside of 418.43%. Given Oculis’ stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Xeris Biopharma.

Risk and Volatility

Xeris Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Insider and Institutional Ownership

42.7% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.3% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Xeris Biopharma and Oculis”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xeris Biopharma $291.85 million 10.40 $550,000.00 ($0.05) -332.40
Oculis $1.45 million 297.50 -$119.44 million ($1.71) -4.35

Xeris Biopharma has higher revenue and earnings than Oculis. Xeris Biopharma is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Summary

Xeris Biopharma beats Oculis on 8 of the 14 factors compared between the two stocks.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

About Oculis

(Get Free Report)

Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.